Overall Survival of Patients With -Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study.

Purpose: The overall survival (OS) results in patients with -positive metastatic non-small-cell lung cancer (NSCLC) have rarely been reported. The aim of this prospective-retrospective cohort study was to obtain real-world data on the use of crizotinib or chemotherapy in patients with -positive metastatic NSCLC in Russia.

Patients And Methods: Patients with epidermal growth factor receptor-negative metastatic NSCLC were screened in 23 cancer centers.

[Problems of rehabilitation and prophylaxis of adverse reactions to antiestrogen therapy in patients with breast cancer].

The principles of specific rehabilitation in females with hormone sensitive breast cancer depending on the type of the antiestrogen hormonotherapy are described. According to the different mechanisms of action of the antiestrogen blockers impact (blocking of estrogen receptors, steroid and nonsteroid aromatase inhibition) programs for rehabilitation depending on the different spectra of antiestrogen therapy side effects were designed.

[Patient care in programmed relaparotomy].

The authors have analyzed the results of treatment of 35 patients, in whom theylaparostoma put on. The mortality have constituted 45.7%.

[Sclerotherapy in surgical correction of varicocele].

The method of intraoperative sclerotherapy, using 40% glucose solution, for varicocele surgical treatment was proposed. Diathermocoagulation of all visible accompanying veins was conducted for reduction of the varicocele recurrence rate. The recurrence is reduced to 6.

[Monoclonal antibody therapy with mabtera of patients with b-cell low grade non-Hodgkin's lymphoma].

The data on monoclonal antibody monotherapy (mabtera, rituximab) in 44 patients with B-cell low grade non-Hodgkin's lymphoma were assessed. Thirty-four of them had received several courses of second- or third line chemotherapy: mabtera was used as first-line therapy in 10. Mabtera was administered in a dose of 375 mg/m2 body surface, once a week, by slow intravenous infusion, 4-14 times depending on effect.